ERBB3 and breast carcinoma: In the SOLTI TOT-HER3 trial (NCT04610528 part A), a window-of-opportunity trial evaluating a single dose of HER3-DXd in patients with treatment-naive HR+/HER2− early breast cancer, HER3-DXd was associated with clinical response, increased immune infiltration, and suppression of proliferation [34].